Angelini Pharma
Angelini is committed to identifying health solutions with a prevalent focus on the areas of Central Nervous System (CNS), including pain, and Rare Diseases. The Company is also a leading player in the Consumer Health sector,
News & publications
-
The third issue of Aptitude Magazine. Discover our stories, let’s browse the magazine
In this issue, you'll find exciting news and original stories, a focus on our commitment on Epilepsy and our strategy to becoming a recognized Employer of Choice.
-
ONTOZRY® (cenobamate) receives European Commission approval for the treatment of drug-resistant focal-onset seizures in adults
Angelini Pharma announced today that the EC has granted marketing authorization for ONTOZRY®.
-
Epilepsy: talking about it at work is still a taboo
Four thousand European citizens were interviewed by SWG on behalf of Angelini Pharma on the occasion of the Purple Day, the international day of awareness about epilepsy. According to the majority of respondents, people with epilepsy are perfectly normal people, but 40% would not talk about the disease at work.
Media center
Core areas
-
Mental Health
The burden of mental health conditions is on the rise globally and major depression, bipolar mood disorder and schizophrenia are among the 10 leading causes of disability worldwide.
-
Central Nervous System
One of the most common brain conditions is epilepsy, which affects over 70 million people worldwide. Epilepsy has numerous neurobiological, cognitive, and psychosocial consequences. In many parts of the world, the disease is stigmatised.
-
Rare Diseases
A disease is defined as rare when its prevalence, that is the number of cases present at a given time in a given population, does not exceed a certain threshold. In the European Union this threshold is set at 0.05% of the population.
-
Consumer Health
Angelini has always recognized and supported the empowerment of patients even in the therapeutic approach of responsible self-medication, in keeping with the fundamental criteria of appropriate drug utilisation.
DISCOVER THE SELECTION OF ARTICLES FROM
From Pipeline to health aids
-
Pipeline
The R&D mission is built on the dynamic pipelini concept, where each project can be partially or fully developed in-house or through collaborative partnership
-
Investigator Initiated Trials
We believe in the value of supporting scientifically and clinically study Investigator Initiated Trials.
-
Sites
All sites use the most advanced technologies, with automatic control and supervision systems. Analysis and quality control, right from the raw material stage, are particularly stringent.
Angelini Pharma Worldwide
